The United States Food and Drug Administration (USFDA) has completed inspection at Unit VII of Aurobindo Pharma. The Company’s Unit VII, an oral manufacturing facility situated at Jedcherla, Hyderabad, received an Establishment Inspection Report (EIR) mentioning the inspection a Voluntary Action Initiated (VAI) from the USFDA and with this inspection is concluded.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
